Related Experiment Video
Updated: Jun 9, 2026
10:35
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
CyberKnife radiosurgery for prostate cancer.
1Flushing Radiation Oncology, 40-20 Main St., Flushing, NY 11354, USA. akatzmd@msn.com
Technology in Cancer Research & Treatment
|September 7, 2010
Summary
Stereotactic Body Radiation Therapy (SBRT) shows promise for prostate cancer treatment, offering effective outcomes with low toxicity. Emerging data support SBRT as a viable option, addressing previous controversies in radiation oncology.
Area of Science:
- Radiation oncology
- Prostate cancer treatment
- Stereotactic Body Radiation Therapy (SBRT)
Background:
- Prostate cancer treatment with SBRT remains controversial despite radiobiologic evidence supporting its efficacy.
- Recent studies indicate favorable outcomes and reduced toxicity with CyberKnife SBRT for prostate cancer.
Purpose of the Study:
- To present the rationale for utilizing SBRT in prostate cancer management.
- To critically evaluate existing literature on prostate cancer SBRT.
- To discuss the future directions of SBRT in treating prostate cancer.
Main Methods:
- Literature review and critical evaluation of current studies on prostate cancer SBRT.
- Analysis of outcomes and toxicity data from SBRT treatments.
- Discussion of radiobiologic principles relevant to SBRT for prostate cancer.
Main Results:
- Emerging data demonstrate promising efficacy for SBRT in prostate cancer treatment.
- CyberKnife SBRT specifically shows minimal toxicity and positive patient outcomes.
- Radiobiologic data suggest the prostate is a suitable target for SBRT.
Conclusions:
- SBRT, particularly with CyberKnife, is emerging as a safe and effective treatment for prostate cancer.
- Further research and evaluation of SBRT are warranted to solidify its role in prostate cancer care.
- The findings challenge previous controversies surrounding SBRT for prostate cancer.
